Right Tools, Right Time, Right Place: Telehealth for Opioid Use Disorder in Vulnerable Settings

Boulder Care

Status and phase: Enrolling; Phase 1

Conditions: Opioid Use Disorder

Treatments: Drug: Telemedicine Buprenorphine Treatment

Study type: Interventional

Funder types: Industry; NIH

Identifiers

NCT07169409

4R44DA061386 (U.S. NIH Grant/Contract)

1R44DA061386-01 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

Our primary objective is to evaluate the ability of Boulder Care's telehealth-platform to create the necessary paradigmatic shift in Opioid Use Disorder (OUD) treatment to reach vulnerable populations, with targets that support both equitable and culturally-specific OUD treatment as well as business profitability.

Enrollment: 250 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• History of Opioid Use Disorder (OUD)
• Starting OUD treatment with buprenorphine, or within 45 days of starting or restarting this medication
• Speak and understand English

Exclusion criteria

• History of allergic reaction to buprenorphine
• Plans to move out of a Boulder Care-affiliated state site in the next 12 months (precluding continuation of care)
• Untreated mental or medical health conditions that, in the opinion of the participant, would preclude study participation

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

250 participants in 1 patient group

Receiving Intervention

Experimental group

Treatment:

Drug: Telemedicine Buprenorphine Treatment